ADMA Biologics, Inc. Annual report pursuant to Section 13 and 15(d)

8. STOCKHOLDERS' EQUITY (Details 3) - USD ($)	12 Months Ended
8. STOCKHOLDERS' EQUITY (Details 3) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Total stock-based compensation expense	$ 2,650,777	$ 2,223,288
Research and Development Expense
Total stock-based compensation expense	360,569	292,739
Plasma centers [Member]
Total stock-based compensation expense	51,340	34,797
Selling, General and Administrative Expense
Total stock-based compensation expense	2,047,025	1,739,037
Cost of goods sold
Total stock-based compensation expense	$ 191,843	$ 156,718